Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Cancer Discovery|September 11, 2012
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1Lauren Averett Byers, Jing Wang, Monique B Nilsson, et al.Cancer Cell|February 14, 2023
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistanceMonique B Nilsson, Yan Yang, Simon Heeke, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 17, 2020
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver MutationsMarcelo V Negrao, Victoria M Raymond, Richard B Lanman, et al.Biorxiv : the Preprint Server for Biology|June 25, 2020
Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 18, 2021
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 PathophysiologyC Allison Stewart, Carl M Gay, Kavya Ramkumar, et al.Cancer Cell|July 12, 2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivityYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 18, 2026
Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIsMonique B Nilsson, Xiuning Le, Alissa Poteete, et al.Nature|September 16, 2021
Structure-based classification predicts drug response in EGFR-mutant NSCLCJacqulyne P Robichaux, Xiuning Le, R S K Vijayan, et al.Cancer Cell|October 8, 2019
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityJacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 25, 2026
Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen ExposureBo Zhu, Muhammad Aminu, Pingjun Chen, et al.Pageof 5